|
NR 10-12/2007
|
|
|
|
|
|
|
|
|
Wyniki leczenia
wysiękowej postaci zwyrodnienia plamki związanego z wiekiem
iniekcjami doszklistkowymi ranibizumabu
– doniesienie wstępne
The results of wet AMD
treatment by intravitreal injections
– preliminary report
Anna Okruszko1, Anna I.
Borucka1,2, Magdalena Ulińska1,2, Jerzy
Szaflik1
1 Z Katedry i Kliniki Okulistyki II Wydziału
Lekarskiego Akademii Medycznej w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik
2 Z Centrum Okulistycznego „Laser” w Warszawie
Kierownik: dr n. med. Jacek P. Szaflik |
|
|
| Summary: |
Age-related macular
degeneration (AMD) is the leading cause of irreversible,
severe loss of vision in the developed countries.
Age-related macular degeneration (AMD) is the leading
cause of irreversible, severe loss of vision in the
developed countries. One of the modern methods of
treatment in neovascular form of AMD are repeated
intravitreal injections of ranibizumab (Lucentis®).
Ranibizumab is a recombinant, humanized, monoclonal
antibody that neutralizes all biologically active forms
of vascular endothelial growth factor A (VEGF-A).
The aim of the study was to analyze the results of
intravitreal ranibizumab injections in wet AMD patients.
There were 57 patients enrolled in the study. 87% of
them avoided any loss of visual acuity and 47.3% gained
at least one line at visual acuity chart. Authors
conclude that treatment with repeated intravitreal
injections of ranibizumab is effective in neovascular
form of AMD. |
| Słowa kluczowe: |
zwyrodnienie plamki
związane z wiekiem, AMD, neowaskularyzacja
naczyniówkowa, ranibizumab, doszklistkowe iniekcje. |
| Key words: |
age-related macular
degeneration, AMD, choroidal neovascularization,
ranibizumab, intravitreal injection. |
|
|
|
|
|
|
